Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.

ABSTRACT:

Introduction

Despite antiretroviral (ARV) therapy reducing renal disease in human immunodeficiency virus overall, there is concern that certain ARVs, particularly tenofovir disoproxil fumarate (TDF) with or without a boosted protease inhibitor (PI), may reduce renal function over time. It is not known whether effects seen with PI-based regimens are independent, result from interactions with TDF coadministration, or are artefactual owing to inhibition of renal tubular creatinine transport by ritonavir or cobicistat pharmacoenhancement. The aim of this review was to conduct a systematic review of studies, weighted toward high-quality evidence, examining changes in renal function over time with PI-based regimens.

Methods

PubMed, Embase, and Medline databases and conference abst

SUBMITTER: Bagnis CI 

PROVIDER: S-EPMC4363218 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature